Literature DB >> 8135187

Measurement of the intensity of cell surface antigen expression in B-cell chronic lymphocytic leukemia.

T E Witzig1, C Y Li, A Tefferi, J A Katzmann.   

Abstract

Immunophenotyping of peripheral blood lymphocytes from 95 patients with B-cell chronic lymphocytic leukemia (B-CLL) was performed to estimate surface membrane intensity of the HLA-DR, CD20, and light-chain antigens. Cases were classified as having weak, moderate, or strong intensity by a standard slide immunocytochemical method, and the fluorescence intensity (FI) was measured by flow cytometry in molecules of equivalent soluble fluorescence (MESF). Staining intensity was strongest for HLA-DR; with both methods, 94 cases were classified as strong. For CD20, 67% were weak, 27% moderate, and 6% strong; the mean MESF values were 31.7, 66.4, and 177.4 x 10(3), respectively (P < .001). Thirty-nine percent had weak surface light-chain staining, 50% moderate, and 11% strong; the mean MESF values were 4.9, 7.5, and 16 x 10(3), respectively (P = .005). These results indicate that the FI of cell surface antigens can be estimated and quantified by flow cytometry. Because of the wide overlap of FI values among the three groups, an exact correlation was not found between the two methods of classifying intensity of surface antigen expression. The usefulness of these quantitative measurements needs further analysis in clinical trials.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8135187     DOI: 10.1093/ajcp/101.3.312

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  3 in total

1.  Levels of expression of CD19 and CD20 in chronic B cell leukaemias.

Authors:  L Ginaldi; M De Martinis; E Matutes; N Farahat; R Morilla; D Catovsky
Journal:  J Clin Pathol       Date:  1998-05       Impact factor: 3.411

2.  An approach for diagnosing plasma cell myeloma by three-color flow cytometry based on kappa/lambda ratios of CD38-gated CD138(+) cells.

Authors:  Shoko Nakayama; Taiji Yokote; Yuji Hirata; Kazuki Iwaki; Toshikazu Akioka; Takuji Miyoshi; Ayami Takayama; Uta Nishiwaki; Yuki Masuda; Toshiyuki Ikemoto; Hidema Tanaka; Yasuichiro Nishimura; Motomu Tsuji; Toshiaki Hanafusa
Journal:  Diagn Pathol       Date:  2012-09-28       Impact factor: 2.644

Review 3.  Current State of CAR T-Cell Therapy in Chronic Lymphocytic Leukemia.

Authors:  Veronika Mancikova; Michal Smida
Journal:  Int J Mol Sci       Date:  2021-05-24       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.